Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Isatuximab,Pomalidomide,Dexamethasone
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Sarclisa (isatuximab) is a antibody that binds to a specific epitope on the CD38 receptor on multiple myeloma (MM) cells. It is being evaluated in phase 3 clinical trials in combination with carfilzomib, lenalidomide & dexamethasone (KRd) for the treatme...
Brand Name : Sarclisa
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 11, 2023
Lead Product(s) : Isatuximab,Pomalidomide,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Isatuximab-irfc,Pomalidomide,Dexamethasone
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Latest results from Phase 3 IKEMA clinical trial for Sarclisa®(isatuximab-irfc) in combination with carfilzomib and dexamethasone demonstrated a median PFS of 35.7 months, compared to 19.2 months in patients treated with Kd alone.
Brand Name : Sarclisa
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 15, 2022
Lead Product(s) : Isatuximab-irfc,Pomalidomide,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Isatuximab,Pomalidomide,Dexamethasone
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Blackstone Life Sciences
Deal Size : $330.0 million
Deal Type : Collaboration
Details : For the Sarclisa® subcutaneous formulation delivery, Sanofi has partnered with drug delivery technology innovator company to advance the development of a subcutaneous delivery for Sarclisa® with the goal of offering a unique patient-centric treatment e...
Brand Name : Sarclisa
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 15, 2022
Lead Product(s) : Isatuximab,Pomalidomide,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Blackstone Life Sciences
Deal Size : $330.0 million
Deal Type : Collaboration
Lead Product(s) : Isatuximab-irfc,Pomalidomide,Dexamethasone
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SARCLISA® continues to be evaluated in multiple ongoing Phase 3 clinical trials in combination with current standard treatments across the MM treatment continuum. It is also under investigation for the treatment of other hematologic malignancies and sol...
Brand Name : Sarclisa
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 13, 2021
Lead Product(s) : Isatuximab-irfc,Pomalidomide,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Isatuximab-irfc,Pomalidomide,Dexamethasone
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Sarclisa is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity.
Brand Name : Sarclisa
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 19, 2021
Lead Product(s) : Isatuximab-irfc,Pomalidomide,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Isatuximab-irfc,Pomalidomide,Dexamethasone
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The decision follows the Phase III IKEMA trial, which featured 302 patients with relapsed multiple myeloma across 69 centers spanning 16 countries. The study found that Sarclisa added to Kd reduced the risk of disease progression or death by 45%, versus ...
Brand Name : Sarclisa
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 31, 2021
Lead Product(s) : Isatuximab-irfc,Pomalidomide,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pomalidomide
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Natco Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Breckenridge Announces Final Approval of its ANDA for Pomalidomide Capsules (Generic for Pomalyst®)
Details : U.S. Food and Drug Administration has approved Breckenridge’s Abbreviated New Drug Application for Pomalidomide Capsules (generic for Pomalyst®).
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 13, 2020
Lead Product(s) : Pomalidomide
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Natco Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Isatuximab-irfc,Pomalidomide,Dexamethasone
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sanofi's Sarclisa Bags NICE Recommendation
Details : Sarclisa (isatuximab) has been recommended in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma who have received three prior lines of treatment, including lenalidomide and proteasome inhibitor.
Brand Name : Sarclisa
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 16, 2020
Lead Product(s) : Isatuximab-irfc,Pomalidomide,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Isatuximab,Pomalidomide,Dexamethasone
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SARCLISA™ in combination with pom-dex significantly reduced the risk of disease progression or death by 40% compared to pom-dex alone in a pivotal trial.
Brand Name : Sarclisa
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 08, 2020
Lead Product(s) : Isatuximab,Pomalidomide,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Isatuximab,Pomalidomide,Dexamethasone
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : EC approval based on data from first randomized Phase 3 trial (ICARIA-MM) to report results evaluating an anti-CD38 monoclonal antibody combined with pomalidomide and dexamethasone (pom-dex).
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 02, 2020
Lead Product(s) : Isatuximab,Pomalidomide,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable